JP2022531454A5 - - Google Patents

Info

Publication number
JP2022531454A5
JP2022531454A5 JP2021565883A JP2021565883A JP2022531454A5 JP 2022531454 A5 JP2022531454 A5 JP 2022531454A5 JP 2021565883 A JP2021565883 A JP 2021565883A JP 2021565883 A JP2021565883 A JP 2021565883A JP 2022531454 A5 JP2022531454 A5 JP 2022531454A5
Authority
JP
Japan
Prior art keywords
muc16
seq
sequence number
nos
includes sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021565883A
Other languages
English (en)
Japanese (ja)
Other versions
JP7675016B2 (ja
JP2022531454A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031886 external-priority patent/WO2020227538A1/en
Publication of JP2022531454A publication Critical patent/JP2022531454A/ja
Publication of JP2022531454A5 publication Critical patent/JP2022531454A5/ja
Application granted granted Critical
Publication of JP7675016B2 publication Critical patent/JP7675016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021565883A 2019-05-08 2020-05-07 ムチン－１６に対するヒト化抗体およびそれを使用する方法 Active JP7675016B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962845065P 2019-05-08 2019-05-08
US62/845,065 2019-05-08
PCT/US2020/031886 WO2020227538A1 (en) 2019-05-08 2020-05-07 Humanized antibodies to mucin-16 and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022531454A JP2022531454A (ja) 2022-07-06
JP2022531454A5 true JP2022531454A5 (https=) 2023-05-12
JP7675016B2 JP7675016B2 (ja) 2025-05-12

Family

ID=73051378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021565883A Active JP7675016B2 (ja) 2019-05-08 2020-05-07 ムチン－１６に対するヒト化抗体およびそれを使用する方法

Country Status (5)

Country Link
EP (1) EP3966248A4 (https=)
JP (1) JP7675016B2 (https=)
KR (1) KR20220007873A (https=)
CN (1) CN114127116A (https=)
WO (1) WO2020227538A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
JP7538601B2 (ja) 2017-04-26 2024-08-22 ユーリカ セラピューティックス， インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
CN113366022B (zh) 2018-11-16 2025-11-21 纪念斯隆凯特琳癌症中心 针对粘蛋白-16的抗体及其使用方法
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
WO2022197907A2 (en) * 2021-03-18 2022-09-22 Memorial Sloan-Kettering Cancer Center Methods for treating gynecologic cancer using combination therapy with anti-muc16 x cd3 multispecific antibodies and vegf inhibitors
WO2022204249A1 (en) * 2021-03-24 2022-09-29 Memorial Sloan-Kettering Cancer Center Variants of humanized anti-muc16 ectodomain antibodies for treatment of muc16 overexpressing tumors
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3255551A1 (en) * 2010-03-26 2025-04-15 Memorial Sloan-Kettering Cancer Center MUC16 ANTIBODIES AND METHODS OF USE
CN113684185A (zh) * 2013-02-26 2021-11-23 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
SG11201707538XA (en) * 2015-03-17 2017-10-30 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
SG10202110182PA (en) * 2017-03-15 2021-10-28 Silverback Therapeutics Inc Benzazepine compounds, conjugates, and uses thereof
WO2018231759A1 (en) * 2017-06-12 2018-12-20 Obsidian Therapeutics, Inc. Pde5 compositions and methods for immunotherapy
WO2019079357A1 (en) * 2017-10-17 2019-04-25 Silverback Therapeutics, Inc. Tnik modulators, conjugates, and uses thereof

Similar Documents

Publication Publication Date Title
JP2022531454A5 (https=)
JP6823094B2 (ja) Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
CN102264765B (zh) 抗muc1抗体
CN103396486A (zh) 使用抗ereg抗体的癌症的诊断和治疗
JP2008538919A5 (https=)
EP1948680A2 (en) Methods and compounds for lymphoma cell detection and isolation
JP2022513050A5 (https=)
JP2013138638A (ja) 抗活性型ｇｉｐ抗体及びその利用
EP4143573A1 (en) Neutralizing antibody assay for therapeutic proteins
JP2001508052A (ja) ホジキンリンパ腫（Ｈｏｄｇｋｉｎ’ｓ ｌｙｍｐｈｏｍａ）の診断および治療方法
WO2005023301A1 (ja) 胆管癌治療剤および検出薬
US20140356365A1 (en) Prognostic, screening and treatment methods and agents for treatment of metstasis and inflammation using t54 oncofoetal glycoprotein
US10145849B2 (en) Monoclonal antibody against necrosis marker PRDX4 and use thereof
CN101505791A (zh) 使用抗桥粒芯蛋白3抗体的癌症的诊断和治疗
RU2707755C2 (ru) Способ прогнозирования риска возникновения рака или диагностирования рака у женщины
EP2203747B1 (en) Anti-calcitonin antibody
JP2007501616A5 (https=)
JP2022526131A (ja) 肝細胞癌診断用バイオマーカーセレブロンと、これに特異的な新規なモノクローナル抗体
RU2701730C2 (ru) Способ прогнозирования риска развития рака или диагностирования рака у индивидуума
US8540991B2 (en) Monoclonal antibodies against PCBP-1 antigens, and uses therefor
KR101380057B1 (ko) 췌장암의 진단제 및 치료제
US20110123441A1 (en) Novel greb1a monoclonal antibody
JP7023942B2 (ja) 卵巣癌バイオマーカーおよびその使用
WO2012000062A1 (en) Diagnosis and treatment of brain tumors
CN113508141A (zh) 抗体及其功能片段